8-K: Phio Pharmaceuticals Reports Positive Clinical Trial Update and Second Quarter 2024 Financial Results

Phio Pharmaceuticals announced positive safety data from its Phase 1b clinical trial, along with second quarter 2024 financial results and a business update.

Summary

• Phio Pharmaceuticals reported its financial results for the quarter ended June 30, 2024, and provided a business update.
• The Phase 1b clinical trial for PH-762 received a positive safety recommendation from the Safety Monitoring Committee, with no dose-limiting toxicities observed in the initial cohort.
• The company has added a fifth clinical trial site for the PH-762 study.
• A new patent was granted in South Korea for INTASYL compounds targeting aging skin disorders.
• Phio exercised warrants for approximately $3.1 million in gross proceeds.
• A reverse stock split of 9:1 was completed on July 5, 2024, reducing outstanding shares from approximately 4.6 million to 0.5 million.
• The company received notice from Nasdaq on July 19, 2024, confirming compliance with the minimum $1.00 bid price requirement.
• Robert M. Infarinato was appointed as Vice President and Chief Financial Officer, effective August 1, 2024.
• Phio is exploring a collaboration with a global skin care company for cosmeceutical applications.
• The company's cash position was $4.7 million as of June 30, 2024, compared to $8.5 million at the end of 2023.
• The company expects to receive approximately $2.6 million in net proceeds from warrant exercises in July 2024.
• Research and development expenses decreased by 37% to $0.9 million for the three months ended June 30, 2024, compared to $1.4 million in the same period of 2023.
• General and administrative expenses decreased by 10% to $1.0 million for the three months ended June 30, 2024, compared to $1.2 million in the same period of 2023.
• The net loss for the quarter was $1.8 million, compared to $2.5 million for the same period in 2023.

Sentiment

Score: 7

Explanation: The document presents a mix of positive clinical trial updates and cost reductions, but also highlights a decrease in cash and the need for further capital raises. The overall sentiment is cautiously optimistic.

Positives

• The Phase 1b clinical trial for PH-762 showed positive safety results, allowing for dose escalation.
• The addition of a fifth clinical trial site expands the reach of the PH-762 study.
• The new patent in South Korea strengthens the company's intellectual property portfolio.
• The exercise of warrants provided $3.1 million in gross proceeds.
• The company is now compliant with Nasdaq's minimum bid price requirement.
• The appointment of a new CFO brings financial expertise to the management team.
• The exploratory collaboration with a skin care company could lead to new revenue streams.
• The company has reduced both research and development and general and administrative expenses.
• The net loss has decreased compared to the same quarter last year.

Negatives

• The company's cash position decreased from $8.5 million at the end of 2023 to $4.7 million as of June 30, 2024.
• The company has incurred a net loss of $1.8 million for the quarter.
• The company has had to raise capital through the exercise of warrants at a reduced price.

Risks

• The company's cash position has decreased significantly, raising concerns about future funding.
• The company is still incurring losses, which may require further capital raises.
• The company is dependent on the success of its clinical trials and collaborations.
• The company faces risks related to regulatory approvals and market acceptance of its products.
• The company is subject to the risks of the biotechnology industry, including competition and technological changes.

Future Outlook

The company plans to continue enrolling patients in the Phase 1b clinical trial for PH-762 and is exploring a collaboration with a global skin care company. The company expects to receive approximately $2.6 million in net proceeds from warrant exercises in July 2024.

Management Comments

• The company is transitioning from a research company to a product development company.
• The company is focused on advancing its clinical programs and exploring strategic collaborations.

Industry Context

The company is operating in the competitive biotechnology sector, focusing on immuno-oncology and skin care applications. The positive safety data from the clinical trial is a positive development in the immuno-oncology space. The collaboration with a skin care company is a move into a new market segment.

Comparison to Industry Standards

• Phio's cash burn rate is typical for a clinical-stage biotech company, but the decrease in cash on hand is a concern.
• The reduction in R&D expenses is a positive sign of cost management, but it is important to ensure that this does not impact the progress of clinical trials.
• The net loss is in line with other companies at a similar stage of development, but the company needs to demonstrate progress towards profitability.
• The company's focus on RNAi technology is a differentiating factor in the immuno-oncology space, but it faces competition from other companies developing similar therapies.
• The collaboration with a skin care company is a unique approach that could provide a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders may be encouraged by the positive clinical trial results and cost reductions.
• Employees may be affected by the cost rationalization measures.
• Customers may benefit from the development of new therapies.
• Suppliers may be impacted by changes in the company's spending.
• Creditors may be concerned about the company's decreasing cash position.

Next Steps

• Continue enrolling patients in the Phase 1b clinical trial for PH-762.
• Advance the exploratory collaboration with the global skin care company.
• Continue to manage costs and seek additional funding as needed.

Key Dates

Keywords

Phio Pharmaceuticals, INTASYL, PH-762, clinical trial, siRNA, immuno-oncology, biotechnology, reverse stock split, warrants, financial results, skin care, cosmeceutical